Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: A systematic review and meta-analysis of randomized controlled trials
Số trang: 11
Loại file: pdf
Dung lượng: 1.88 MB
Lượt xem: 18
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death, worldwide. The predominant causative factor for HCC is hepatitis B virus (HBV) infection. We conducted a meta-analysis to estimate the efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the first-line treatment of the unresectable HCC and to evaluate the benefits of different geographic regions and etiology stratifications.
Nội dung trích xuất từ tài liệu:
Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: A systematic review and meta-analysis of randomized controlled trials
Nội dung trích xuất từ tài liệu:
Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: A systematic review and meta-analysis of randomized controlled trials
Tìm kiếm theo từ khóa liên quan:
BMC Cancer PD-1 inhibitor PD-L1 inhibitor Anti-angiogenic Hepatitis B Virus Hepatocellular carcinoma Meta-analysisTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 172 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 94 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 44 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0